New activator features a single-piece eye cup and translucent design that allows for more efficient and accurate positioning in the eye.
Johnson & Johnson Vision (JJV) announced last Friday the availability of its next-generation TearScience Activator Clear for the treatment of meibomian gland dysfunction (MGD).
The new technology is designed on the legacy of JJV’s TearScience LipiFlow Thermal Pulsation System, which is a fully-automated MGD treatment, according to a news release.
The TearScience Activator Clear includes a single-piece eye cup and translucent design that enables a more efficient and accurate positioning in the eyes, allowing for a more even application of heat and pressure across the entire eyelid.
Additionally—with a more environmental focus—it was created using a redesigned manufacturing process and fewer raw materials than the previous version.
A recent study published in Clinical Ophthalmology, assessed the clinical use of the LipiFlow system with the TearScience Activator Clear to successfully complete Lipiflow treatments. Investigators, led by Jerry G. Hu, MD, of Texas Eye & Laser in Fort Worth and Hurst, Texas, conducted a prospective, open-label clinical investigation on 44 participants (88 eyes) who were diagnosed with bilateral MDD.
Both eyes of all subjects received treatment using the LipiFlow system with the TearScience Activator Clear.
Researchers then completed a questionnaire that assessed the clinical use of the TearScience Activator Clear on a 5-point scale, with 1 equaling very difficult or strongly disagree and 5 equaling very easy or strongly difficult.
Investigators reported that the TearScience Activator Clear provided successful LipiFlow treatment in 100% of cases, with a 95% confidence interval of 96%, 100%. Further, they agreed or strongly agreed that the TearScience Activator Clear’s translucent components made it easy to access and position the activator with confidence on subjects’ eyes.
TearScience Activator Clear is currently available for use by eyecare professionals to treat MGD patients with the LipiFlow system in the US, Canada, Hong Kong, Chile, and Argentina. JJV expects to continue its rollout to additional countries throughout 2022.